Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinomic Profiling Using Patient-Derived Cell Lines Predicts Sensitivity to Imatinib in Dermatofibrosarcoma Protuberans.

Cells·2025
Same author

The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment.

Cancer immunology research·2024
Same author

Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations.

Molecular cancer·2024
Same author

Harnessing the potential of reverse-phase protein array technology: Advancing precision oncology strategies.

Cancer science·2024
Same author

Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti-PD-1 Immunotherapy in Fibrotic Tumors.

Cancer research·2022
Same author

Structural Insight into TNIK Inhibition.

International journal of molecular sciences·2022

Related Experiment Video

Updated: Feb 28, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K

Signaling pathway profiling using reverse-phase protein array and its clinical applications.

Mari Masuda1, Tesshi Yamada1

  • 1a Division of Chemotherapy and Clinical Research , National Cancer Center Research Institute , Tokyo , Japan.

Expert Review of Proteomics
|June 17, 2017
PubMed
Summary

Precision medicine uses genomics for cancer treatment, but protein analysis is needed for durable efficacy. Antibody-based reverse-phase protein array (RPPA) offers a cost-effective proteomic solution for personalized cancer care.

Keywords:
Reverse-phase protein array (RPPA)biomarker panelmolecular targeting agentspatient stratificationprecision medicineprotein phosphorylationsignal pathway profiling

More Related Videos

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.2K
Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions
06:01

Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions

Published on: January 7, 2019

7.7K

Related Experiment Videos

Last Updated: Feb 28, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.2K
Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions
06:01

Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions

Published on: January 7, 2019

7.7K

Area of Science:

  • Oncology
  • Proteomics
  • Genomics

Background:

  • Next-generation sequencing has advanced cancer treatment towards precision medicine.
  • Current genomic and transcriptomic approaches have limitations in predicting protein expression and modifications.
  • Durable efficacy in cancer treatment remains a challenge.

Purpose of the Study:

  • To review advances in precision medicine.
  • To highlight the utility of antibody-based reverse-phase protein array (RPPA) technology in precision medicine.
  • To underscore the need for proteomic analysis in cancer treatment.

Main Methods:

  • Review of recent advances in precision medicine.
  • Discussion of antibody-based reverse-phase protein array (RPPA) technology.
  • Analysis of RPPA's suitability for pharmacodynamics and clinical applications.

Main Results:

  • Genomic approaches alone are insufficient for fully personalized cancer therapy.
  • RPPA technology enables precise mapping of signaling status using limited clinical samples.
  • RPPA is cost-effective and offers rapid turnaround time compared to other molecular profiling technologies.

Conclusions:

  • Proteomic analysis, particularly RPPA, is crucial for the next stage of precision medicine.
  • RPPA is well-suited for pharmacodynamics analysis in clinical settings.
  • The advantages of RPPA make it a valuable tool for advancing personalized cancer treatment.